CHMP Expands Repatha to High-Risk ASCVD Adults
CHMP Repatha high risk atherosclerotic cardiovascular disease expansion widens who can use evolocumab to cut CV risk by lowering LDL-C. On 23 July 2026 EMA's committee backed adults with established or high-risk ASCVD, including statin-intolerant patients, as an adjunct to other risk-factor correction.
Contents11 sections
Key Takeaways
- CHMP recommended expanding Repatha's CV-risk indication to adults with established or high-risk ASCVD.
- High-risk examples cited: myocardial infarction, stroke or peripheral arterial disease risk settings.
- Use remains adjunctive to diet/risk-factor correction, alone or with max-tolerated statin or other lipid therapies.
- Hypercholesterolaemia and HoFH paediatric/adult indications stay on the draft full label.
Repatha ASCVD expansion at a glance
| Field | Detail |
|---|---|
| Product | Repatha (evolocumab) |
| Company | Amgen Europe B.V. |
| Regulator action | CHMP positive variation opinion (23 July 2026) |
| Label change | ASCVD CV-risk reduction broadened to established or high-risk adults |
| Mechanism class | PCSK9 inhibitor monoclonal antibody |
| Companion uses | Primary hypercholesterolaemia / mixed dyslipidaemia; HoFH |
| Next step | European Commission decision |
What wording did CHMP adopt?
EMA's Repatha variation page says that on 23 July 2026 CHMP adopted a positive opinion recommending a change to the marketing authorisation. The extended cardiovascular indication states Repatha is indicated in adults with established or at high risk for atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors, either with maximum tolerated statin therapy or alone/with other lipid-lowering therapies in statin-intolerant or statin-contraindicated patients.
Primary source: EMA's Repatha variation opinion.
What else stays on the EU label?
The draft full indications continue to cover primary hypercholesterolaemia or mixed dyslipidaemia in adults and heterozygous familial hypercholesterolaemia from age 10, plus homozygous familial hypercholesterolaemia in adults and children from age 10 in combination with other lipid-lowering therapies. EMA points clinicians to section 5.1 for study results on LDL-C, cardiovascular events and populations studied.
July plenary listing: EMA CHMP highlights 20–23 July 2026.
Why does high-risk primary prevention language matter?
Moving from a narrower established-ASCVD framing toward explicit high-risk eligibility can enlarge the treatable pool for intensive LDL-C lowering when statins are insufficient or not tolerated. Exact operational definitions of "high risk" will sit in the SmPC and national guidelines rather than in the CHMP headline alone.
Product context: EMA Repatha EPAR landing page.
How does this sit beside other July lipid opinions?
The same CHMP plenary also recommended new lipid medicines such as Lyrokaul (lerodalcibep) and the obicetrapib products Ubeslo and Evlarco. Repatha's variation is an expansion of an established PCSK9 antibody rather than a first authorisation, so uptake dynamics will differ from new oral or injectable entrants.
What should cardiology and lipid clinics watch?
- Final SmPC definition of high-risk ASCVD and documentation requirements
- Statin-intolerance criteria used by national HTA bodies
- Injection-device logistics and adherence support for chronic PCSK9 therapy
- Positioning versus emerging CETP and ANGPTL3 / siRNA lipid options
Commission approval is still required before the revised indication is authorised EU-wide.
What remains uncertain?
How broadly member states will reimburse high-risk primary prevention, residual LDL-C goal attainment in polypharmacy patients, and comparative cost-effectiveness versus newer oral agents remain open questions after the opinion.
Related NovaPharma coverage
- CHMP Backs Lyrokaul Monthly PCSK9 Shot
- CHMP Backs Obicetrapib Ubeslo and Evlarco
- CHMP July 2026: 12 New Medicines Recommended
Frequently Asked Questions
How did CHMP change Repatha's cardiovascular indication?
EMA said CHMP recommended indicating Repatha in adults with established or high-risk atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C, as an adjunct to correction of other risk factors.
Can statin-intolerant adults be included?
Yes. The draft wording allows use alone or with other lipid-lowering therapies in patients who are statin-intolerant or for whom a statin is contraindicated, as well as with maximum tolerated statin therapy.
Are the cholesterol and HoFH indications changing?
EMA's draft full indications keep primary hypercholesterolaemia/mixed dyslipidaemia and homozygous familial hypercholesterolaemia uses alongside the expanded ASCVD cardiovascular-risk language.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Repatha.
Unlock full calendar →Amgen pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
